Categories Uncategorized

How Adageis Uses Data to Drive Value-Based Care Adoption and Boost Revenue for Healthcare Providers

  • Value-based care models prioritize proactive, high-quality patient care, and, if done correctly, can significantly enhance financial outcomes.
  • Healthcare organizations adopting a value-based care approach can see increased revenue through efficiency, reduced hospitalizations and incentive payments.
  • Adageis provides AI-driven solutions that help providers transition to and optimize value-based care models.
  • The company’s data analytics features play a critical role in identifying high-risk patients, closing care gaps and controlling costs.

Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services rendered. This approach incentivizes proactive care, chronic disease management and overall cost efficiency.

High-performing healthcare organizations that successfully implement value-based care are seeing not only improved patient outcomes but also increased financial performance. Organizations that excel in value-based care realize revenue growth through:

  • Incentive Payments: Providers receive bonuses for meeting quality and efficiency benchmarks.
  • Cost Savings: Reduced hospitalizations, emergency room visits and redundant tests translate into lower costs.
  • Risk-Based Contracts: Capitated payment models allow providers to share in savings if they deliver care efficiently.
  • Better Resource Allocation: AI-driven insights help providers allocate resources where they are needed most, improving operational efficiency.

Healthcare systems that fail to adapt risk being left behind as government and private payers continue shifting toward value-based care models. But all of this requires an increased and efficient handle on data, providing more effective patient care and comprehensive cost control.

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is helping providers streamline their transition to value-based care. Through its ProActive Care Platform, Adageis enables healthcare organizations to optimize patient care while maximizing financial performance (https://ibn.fm/Y5C6O).

Adageis’ solutions integrate directly with existing electronic health record (“EHR”) systems, ensuring a seamless transition without disrupting workflows. Its key features include:

  • AI-Driven Risk Analysis: Identifies high-risk patients, allowing providers to intervene earlier and prevent costly hospitalizations.
  • Value-Based Care Engine: Helps organizations meet value-based care metrics, unlocking new revenue opportunities.
  • Proactive Efficiency Monitoring: Tracks patient health trends and alerts providers to potential issues before they escalate.
  • Flexible Integration: Compatible with leading EHR systems such as AthenaHealth, Cerner and Epic.

By leveraging advanced analytics and machine learning, Adageis enables providers to shift from reactive to proactive care—essential for success in a value-based care environment.

Additionally, one of the biggest challenges in value-based care is accurately measuring and improving patient outcomes. Adageis addresses this by offering real-time data insights that help providers identify gaps in care and address them proactively, track patient engagement and adherence to treatment plans, predict health trends to optimize resource allocation, and benchmark performance against value-based care reimbursement models.

As the healthcare industry continues its shift toward value-based care, the organizations that embrace technology-driven solutions will have a competitive edge. AI-powered tools, like those developed by Adageis, will play a central role in improving care quality, enhancing efficiency and driving financial growth.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether…

10 hours ago

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology…

2 days ago

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients…

2 days ago

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis)…

3 days ago

Survey Finds That US Healthcare Workers Worry About Personal Safety

According to a new survey, approximately 60% of workers in the U.S. healthcare sector are…

6 days ago

Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results

Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially…

1 week ago